September 20 – 22, 2017 | San Diego, CA

Sheraton San Diego Marina

Press Releases

Here you will find the most up to date news and press releases in the ADC space.

adc-press-release Catalent Biologics and Triphase Accelerator Corporation announce
license agreement to advance smartagtm adc to clinic

 

View here

ADC PRess 1 Fight against cancer > Small molecules – PhenoFrag
View here

 

ADC Fierce AbbVie, Bristol-Myers to combine checkpoint inhibitors, Rova-T in cancer trials
View here

 

ADC Press Celldex Therapeutics Initiates Phase 1/2 Clinical Trial of New Product CandidateView here
Stem and ABBVIE 3 AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx

 

View here

ADC Bio - US$10m cancer drug production expansionADC Bio – US$10m cancer drug production exp

View here

Swissmedic inspection Vionnaz - CARBOGEN expands its ADC capabilitiesCARBOGEN AMCIS Passes Successful Inspection by Swissmedic

View here

Seattle Genetics Completes Enrollment in Phase 3Seattle Genetics Completes Enrollment in Phase 3 ALCANZA Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma (CTCL)

View here

Novasep invests €10M to reinforce its bioconjugation servicesNovasep invests €10M to reinforce its bioconjugation services

View here

Goodwin Biotechnology And Aspyrian Therapeutics Collaborate On The Successful GMP Manufacturing And IND Submission For A Novel Antibody Drug Conjugate (ADC) PlatformGoodwin Biotechnology And Aspyrian Therapeutics Collaborate On The Successful GMP Manufacturing And IND Submission For A Novel Antibody Drug Conjugate (ADC) Platform

View here

Immunomedics Reports Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal CancerImmunomedics Reports Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer

View here

A novel antibody–drug conjugate targetingA novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

View here

Crescendo awarded grant to validate antibody fragment-drug conjugatesCrescendo awarded grant to validate antibody fragment-drug conjugates

View here

safc pdf thumbSAFC® Launches ADC ExpressSM to Expedite Preclinical Antibody Drug Conjugation Services

View here

medical xpress pr

New antibody-drug conjugate shows early promise for patients with metastatic HER2-positive breast cancer

View here

biospace pr

Pfizer (PFE)’s New Leukemia Drug Meets Hematologic Remission Endpoint in Phase III Study

View here

business blend pr

Blend Therapeutics Presents Preclinical Data for Lead Pentarin™ Program, BTP-277, Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer

View here

nasdaq 16.04

Innate Pharma and Sanofi collaborate on next generation antibody-drug conjugates using Innate’s site-specific conjugation technology

View here

San Diego’s Antibody-Drug Conjugate Research

San Diego’s Antibody-Drug Conjugate Research Highlighted at #WorldADC Meeting in October

View here

Catalent Adds Global Particle Size

Catalent Adds Global Particle Size Technology Leader To Industry’s Broadest Bioavailability And Delivery Technology Offerings

View here

NRC and AvidBiologics Progress New Treatments

NRC and AvidBiologics Progress New Treatments to Seek and Destroy Cancer Cells

View here

Asana worldadc

Asana BioSciences presents pre-clinical data for ASN004, an antibody drug conjugate for the treatment of cancer, at the 5th Annual World ADC Summit

View here

Igenica Biotherapeutics to Present New Data on Proprietary

Igenica Biotherapeutics to Present New Data on Proprietary SNAP Antibody Drug Conjugate Technology at Upcoming World ADC Summit

View here

Immunomedics Announces European Orphan Drug Designation

Immunomedics Announces European Orphan Drug Designation for Isactuzumab Govitecan for Pancreatic Cancer Treatment

View here

bicyle therapeutics

Bicycle Therapeutics announces £20M ($32M) million financing for drug development

View here

PRNewswire

Sorrento and Lee’s Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody

View here

oxford biothera

Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance

View here

Catalent Expands Its Technology Offerings In Biologics

Catalent Expands Its Technology Offerings In Biologics, Acquires Redwood Bioscience Inc. And The SMARTag™ Technology Platform

View here

SAFC and Baxter BioPharma Solutions

SAFC and Baxter BioPharma Solutions Collaborate on Complete ADC Offering

View here

Sutro Biopharma and Merck KGaA

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates

View here

CARBOGEN AMCIS Expands Operations in Switzerland

CARBOGEN AMCIS Expands Operations in Switzerland

View here

Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates

Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates

View here

CARBOGEN AMCIS AG Makes Capital Investments in ADC

CARBOGEN AMCIS AG Makes Capital Investments in ADC

View here